Document ID: chunk:federal_register_of_legislation:F2023L01747:schedule:1:p14
Version: federal_register_of_legislation:F2023L01747
Segment Type: schedule
Provision Reference: sch 1 (pt 14/31)
Character Range: 45002–48165

C5618 C10498  P10498  10  1  10

     [77]               Schedule 1, Part 1, entry for Ondansetron in the form Tablet 8 mg (as hydrochloride dihydrate)
         (a)           omit:
         a  Ondansetron APOTEX  GX  MP NP  C4118 C10498  P4118  4  0  4
                                    MP     C5778                4  0  4     C(100)

         (b)           omit:
         a  Ondansetron APOTEX  GX  MP NP  C4118 C10498  P10498  10  1  10

     [78]               Schedule 1, Part 1, entry for Pembrolizumab
         (a)           omit from the column headed "Circumstances": C10687
         (b)           omit from the column headed "Circumstances": C10695
         (c)           insert in numerical order in the column headed "Circumstances": C14770 C14786

     [79]               Schedule 1, Part 1, entry for Pirfenidone in the form Tablet 267 mg
     insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":
         a  Pirfenidet  AF  MP  C13378 C13380 C13381     270  5  90

     [80]               Schedule 1, Part 1, entry for Pirfenidone in the form Tablet 801mg
     insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":
         a  Pirfenidet  AF  MP  C13380     90  5  90

     [81]               Schedule 1, Part 1, entry for Pomalidomide
     insert as first entry:
   Capsule 1 mg  Oral     Pomolide  JU  MP  See Note 3  See Note 3  See Note 3  See Note 3  14     D(100)
                                        MP  See Note 3  See Note 3  See Note 3  See Note 3  21     D(100)
   Capsule 2 mg  Oral     Pomolide  JU  MP  See Note 3  See Note 3  See Note 3  See Note 3  14     D(100)
                                        MP  See Note 3  See Note 3  See Note 3  See Note 3  21     D(100)

     [82]               Schedule 1, Part 1, entry for Pravastatin in each of the forms: Tablet containing pravastatin sodium 10 mg; Tablet containing pravastatin sodium 20 mg; Tablet containing pravastatin sodium 40 mg; and Tablet containing pravastatin sodium 80 mg
         (a)           omit:
         a  APO-Pravastatin  TX  MP NP        30  5  30

         (b)           omit:
         a  APO-Pravastatin  TX  MP NP     P14238  60  5  30

     [83]               Schedule 1, Part 1, entry for Pregabalin in each of the forms: Capsule 25 mg; Capsule 75 mg; Capsule 150 mg; and Capsule 300 mg
     omit:
         a  LYPRALIN  RW  MP NP  C4172     56  5  56

     [84]               Schedule 1, Part 1, entry for Raloxifene
         (a)           omit:
         a  APO-Raloxifene  TX  MP NP  C6314 C14274  P6314  28  5  28

         (b)           omit:
         a  APO-Raloxifene  TX  MP NP  C6314 C14274  P14274  56  5  28

     [85]               Schedule 1, Part 1, entry for Ramipril in the form Tablet 1.25 mg [Maximum Quantity: 30; Number of Repeats: 5]
     insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":
            Ramipril Viatris  AL  MP NP        30  5  30

     [86]               Schedule 1, Part 1, entry for Ramipril in the form Tablet 1.25 mg [Maximum Quantity: 60; Number of